Pharma Services Overview
The rapid advancement of related technologies and dramatic decrease in cost has led next-generation sequencing (NGS) to become a powerful tool for the research and development of medicines by the pharmaceutical industry. From the study of biological mechanisms to the search for predictive biomarkers to the screening of target patients for clinical trials, NGS is increasingly employed in applications of precision medicine. Furthermore, the recent FDA approvals of MSK-IMPACT and F1CDx represent a historical step forward in the application of NGS in clinical diagnosis. Some new treatment modalities (e.g. personalized cancer vaccine) may have even higher demand for NGS.
As the world’s largest NGS service provider, Novogene recognizes this trend and now offers our pharma clients several key clinical-grade assays (see the list below) in our CAP-certified lab in China and our US lab, which will be CLIA-certified in Q1 2018. Additional assays will be added to the list as they are developed and validated. We are fully committed to helping you meet your drug R&D goals with our unparalleled scale, efficiency, quality, and price.